Glaxosmithkline Biologicals Sa competitive analysis

Explore patent oppositions filed by Glaxosmithkline Biologicals Sa against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 10, 2026
Patent NumberTitleApplicantOpposition Date
Ribonucleic Acids Containing N1-Methyl-Pseudouracils And Uses ThereofMODERNAFeb 17, 2023
Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses ThereofMODERNAAug 26, 2022
Methods And Compositions For Delivering Mrna Coded AntibodiesSHIRE HUMAN GENETIC THERAPIESFeb 18, 2022
Engineered Nucleic Acids And Methods Of Use ThereofMODERNASep 30, 2021
Improved Methods For Preparing SqualeneNOVARTISApr 15, 2021
Cleavable LipidsTRANSLATE BIOJan 15, 2021
Vaccination With Multiple Clades Of H5 Influenza A VirusNOVARTISMay 20, 2020
Manufacture Of An Oil-In-Water Emulsion Comprising SqualeneNOVARTISNov 6, 2019
Stable Aqueous Formulations Of Adenovirus VectorsARECORMay 23, 2018
Modified Bordetella Pertussis StrainsBIONET ASIAFeb 9, 2018

Explore Glaxosmithkline Biologicals Sa's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 10, 2026
Patent NumberPublication DateTitleTotal Oppositions
Aug 12, 2026Fermentation Processes For Cultivating Streptococci And Purification Processes For Obtaining Cps Therefrom1
Feb 26, 2025Rsv Immunization Regimen1
Feb 26, 2025Rsv Immunization Regimen1
Oct 23, 2024Pegylated Liposomes For Delivery Of Immunogen-Encoding Rna5
Nov 29, 2023Expression System1
Nov 1, 2023Immunogenic Composition1
Mar 1, 2023Small Liposomes For Delivery Of Immunogen-Encoding Rna4
Jan 11, 2023Small Liposomes For Delivery Of Immunogen-Encoding Rna5
Dec 28, 2022Small Liposomes For Delivery Of Immunogen-Encoding Rna5
Dec 28, 2022Pegylated Liposomes For Delivery Of Immunogen-Encoding Rna4

Latest PTAB cases involving Glaxosmithkline Biologicals Sa

Discover the latest PTAB cases involving Glaxosmithkline Biologicals Sa, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 9, 2026
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Glaxosmithkline Biologicals Sa

IPR2020-00962May 27, 2020GLAXOSMITHKLINE BIOLOGICALS SAPFENEXTerminated-Settled
IPR2020-00890May 7, 2020GLAXOSMITHKLINE BIOLOGICALS SAPFENEXTerminated
IPR2019-01478Aug 9, 2019PFENEXGLAXOSMITHKLINE BIOLOGICALS SAInstitution Denied
IPR2019-01027May 6, 2019PFENEXGLAXOSMITHKLINE BIOLOGICALS SAInstitution Denied
IPR2019-01028May 6, 2019PFENEXGLAXOSMITHKLINE BIOLOGICALS SATerminated-Settled
IPR2019-00230Nov 7, 2018MERCK SHARP & DOHMEGLAXOSMITHKLINE BIOLOGICALS SATerminated-Settled
IPR2019-00241Nov 7, 2018MERCK SHARP & DOHMEGLAXOSMITHKLINE BIOLOGICALS SATerminated-Settled
IPR2018-01229Jun 11, 2018MERCK SHARP & DOHMEGLAXOSMITHKLINE BIOLOGICALS SATerminated-Settled
IPR2018-01234Jun 11, 2018MERCK SHARP & DOHMEGLAXOSMITHKLINE BIOLOGICALS SATerminated-Settled
IPR2018-01236Jun 11, 2018MERCK SHARP & DOHMEGLAXOSMITHKLINE BIOLOGICALS SATerminated-Settled

Peer Comparison New

IP litigation analysis comparing Glaxosmithkline Biologicals Sa with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 10, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
GLAXOSMITHKLINE BIOLOGICALS SA2610029
MERCK SHARP & DOHME2656615
NOVARTIS12542 - 21
PFENEX - - 32